Pain Therapeutics (NASDAQ:PTIE) rose 3.3% on Wednesday . The company traded as high as $2.26 and last traded at $2.21, with a volume of 119,257 shares changing hands. The stock had previously closed at $2.14.

Separately, Zacks Investment Research upgraded Pain Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st.

The stock’s market cap is $101.51 million. The company’s 50-day moving average price is $2.18 and its 200 day moving average price is $2.06.

Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.03. On average, equities research analysts predict that Pain Therapeutics will post ($0.57) earnings per share for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.